These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3996141)

  • 1. Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions.
    Benz C; Wiznitzer I; Lee SH
    Cytometry; 1985 May; 6(3):260-7. PubMed ID: 3996141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods.
    McCarty KS; Hiatt KB; Budwit DA; Cox EB; Leight G; Reintgen D; Georgiade G; McCarty KS; Siegler HF
    Arch Pathol Lab Med; 1984 Jan; 108(1):24-6. PubMed ID: 6546332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of ligand binding, E-BSA-FITC.
    Ashcroft RG
    Cytometry; 1986 May; 7(3):298-9. PubMed ID: 3709312
    [No Abstract]   [Full Text] [Related]  

  • 4. Estrogen receptors in human breast cancer. I. Specificity of the histochemical localization of estrogen receptors using an estrogen-albumin FITC complex.
    van Marle J; Lindeman J; Ariens AT; Labruyère W; van Weeren-Kramer J
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1982; 40(1):17-25. PubMed ID: 6126951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estradiol membrane binding sites on human breast cancer cell lines. Use of a fluorescent estradiol conjugate to demonstrate plasma membrane binding systems.
    Berthois Y; Pourreau-Schneider N; Gandilhon P; Mittre H; Tubiana N; Martin PM
    J Steroid Biochem; 1986 Dec; 25(6):963-72. PubMed ID: 3025520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a biotinyl-estradiol derivative to demonstrate estradiol-membrane binding sites on adherent human breast cancer MCF-7 cells.
    Germain PS; Metezeau P; Tiefenauer LX; Kiefer H; Ratinaud MH; Habrioux G
    Anticancer Res; 1993; 13(6A):2347-53. PubMed ID: 8297157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
    Kampa M; Nifli AP; Charalampopoulos I; Alexaki VI; Theodoropoulos PA; Stathopoulos EN; Gravanis A; Castanas E
    Exp Cell Res; 2005 Jul; 307(1):41-51. PubMed ID: 15922725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric determination of estrogen receptors in intact cells.
    Oxenhandler RW; McCune R; Subtelney A; Truelove C; Tyrer HW
    Cancer Res; 1984 Jun; 44(6):2516-23. PubMed ID: 6722791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration.
    Murphy LJ; Murphy LC; Vrhovsek E; Sutherland RL; Lazarus L
    Cancer Res; 1984 May; 44(5):1963-8. PubMed ID: 6324992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of histochemical and biochemical assays for estrogen receptor in human breast cancer cell lines.
    Parl FF; Wetherall NT; Halter S; Schuffman S; Mitchell WM
    Cancer Res; 1984 Jan; 44(1):415-21. PubMed ID: 6690057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of estradiol immunofluorescence in MCF-7 breast cancer cells to detect estrogen receptors.
    Mercer WD; Edwards DP; Chamness GC; McGuire WL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4644-52. PubMed ID: 7030480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
    Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
    Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
    ter Haar E; Hamel E; Balachandran R; Day BW
    Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro.
    Goldenberg GJ; Froese EK
    Cancer Res; 1982 Dec; 42(12):5147-51. PubMed ID: 7139616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol.
    Brandes LJ; Hermonat MW
    Cancer Res; 1983 Jun; 43(6):2831-5. PubMed ID: 6850594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study between histochemical and biochemical estimation of estrogen receptors in tumors.
    De Potter CR; Eechaute W; Roels H; Leusen I
    J Recept Res; 1985; 5(4):245-65. PubMed ID: 2997446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
    Liu ZJ; Zhu BT
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of hormone-receptor interactions by means of fluorescence labeling.
    Dandliker WB; Brawn RJ; Hsu ML; Brawn PN; Levin J; Meyers CY; Kolb VM
    Cancer Res; 1978 Nov; 38(11 Pt 2):4212-24. PubMed ID: 212190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.